Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $404.36M
• Dividend Yield: N/A
• Average Volume (3M): 169.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: -71.42%
• EPS Growth: -248.91%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.06
• Shares Outstanding: 38,219,230
• 10 Day Avg. Volume: 184,920
• 30 Day Avg. Volume: 169,414
• PEG Ratio: -0.01
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 3.06
• P/FCF Ratio: -14.43
• Enterprise Value/Market Cap: -0.08
• Enterprise Value/Revenue: -0.55
• Enterprise Value/Gross Profit: -1.47
• Enterprise Value/Ebitda: 0.30
• 1Y Price Target: $16.50
• Price Target Upside: 52.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -4.22
• Revenue Forecast (FY): $20.18M

• Rating: 52 Neutral
• Price Target: $11.00 ▲(1.66% Upside)

The score is held back primarily by weak financial performance (declining revenue, ongoing losses, and negative cash flows). Offsetting factors include favorable technical trends (price above key moving averages with positive MACD) and a positive corporate update highlighting meaningful pipeline and regulatory progress with runway into Q3 2027; valuation remains challenged due to loss-making status and no dividend data.

Positive Factors

Advanced clinical-stage RNA pipeline & regulatory wins

Regulatory designation and multiple mid-stage DMD programs materially improve long-term program optionality and de-risk timelines versus preclinical assets. Designations can enable priority pathways and incentives, increasing the chance of accelerated development and partner interest over years.

Conservative leverage

Low debt relative to equity provides structural balance-sheet resilience during multi-year clinical development. Limited financial leverage reduces fixed financing costs and bankruptcy risk, preserving flexibility to fund R&D or absorb trial delays without immediate solvency pressure.

Partnerships, collaboration revenue model and partnered programs

A partnership-driven model and ongoing Vertex collaboration provide non-dilutive funding levers, external validation, and potential milestone/royalty upside. Coupled with a reported cash runway into Q3 2027, this supports multi-year development execution absent immediate commercial sales.

Negative Factors

Declining revenue and negative profitability

A sustained revenue decline and persistent negative operating margins signal structural profitability challenges. Without product revenue, ongoing losses will continue to erode equity and limit reinvestment capacity, weakening self-funding prospects and raising long-term dilution risk.

Negative operating and free cash flow

Consistently negative operating and free cash flow reflect an ongoing cash burn inherent to clinical-stage biotechs. This creates execution risk if trials extend or costs rise, forcing reliance on external capital that can dilute shareholders or constrain strategic options long term.

No commercial products; reliance on external financing

Absent commercial sales, the company depends on milestone-based partner payments and equity financing. This model leaves funding and growth tied to partner timelines and capital markets, increasing vulnerability to dilution and to setbacks in trials that can materially impair long-term strategy.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Entrada Therapeutics generates revenue through a combination of product development partnerships, grants, and potential future product sales. The company collaborates with pharmaceutical firms and research organizations to develop its therapies, often receiving milestone payments and royalties from these partnerships. Additionally, Entrada may receive funding from government and non-profit organizations aimed at supporting research in rare and genetic diseases. As the company advances its drug candidates through clinical trials, it may also attract further investments and partnerships, enhancing its revenue potential.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Entrada Therapeutics Inc is facing significant financial challenges, with declining revenues and persistent losses impacting profitability. While the company maintains a stable balance sheet with low leverage, cash flow issues persist. The biotechnology industry often involves high R&D costs and long development cycles, which may contribute to the current financial performance.

Income Statement

Entrada Therapeutics Inc has experienced a significant decline in revenue with a negative growth rate of -22.59% in the TTM period. The company is facing challenges with profitability, as evidenced by negative net profit and EBIT margins. Despite a high gross profit margin, the overall financial performance is hindered by substantial operating losses.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio of 0.15, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is stable, suggesting a solid capital structure despite profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and accounting profits, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.52M	210.78M	129.01M	0.00	0.00	0.00
Gross Profit	23.16M	210.78M	129.01M	0.00	0.00	-326.00K
EBITDA	-113.78M	47.01M	-321.00K	-95.35M	-50.01M	-26.20M
Net Income	-103.45M	65.63M	-6.68M	-94.62M	-51.16M	-26.52M
Balance Sheet
Total Assets	412.90M	526.32M	469.19M	252.06M	305.83M	43.53M
Cash, Cash Equivalents and Short-Term Investments	326.84M	420.00M	351.97M	188.71M	291.06M	39.05M
Total Debt	52.40M	59.21M	68.23M	25.94M	0.00	0.00
Total Liabilities	72.18M	97.64M	226.83M	39.50M	7.12M	85.02M
Stockholders Equity	340.72M	428.68M	242.36M	212.55M	298.72M	-41.49M
Cash Flow
Free Cash Flow	-129.80M	-44.72M	134.19M	-96.67M	-55.44M	-27.89M
Operating Cash Flow	-127.91M	-41.56M	139.80M	-93.79M	-50.86M	-25.57M
Investing Cash Flow	141.05M	-27.80M	-138.40M	-148.65M	-4.58M	-2.32M
Financing Cash Flow	2.10M	102.96M	21.04M	479.00K	307.46M	50.09M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Positive. The current price of 10.82 is above the 20-day moving average (MA) of 10.49, above the 50-day MA of 9.80, and above the 200-day MA of 7.58, indicating a bullish trend. The MACD of 0.15 indicates Positive momentum. The RSI at 57.82 is Neutral, neither overbought nor oversold. The STOCH value of 78.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTYX	63 Neutral	$994.46M	-9.24	-45.35%	―	―	36.65%
BDTX	59 Neutral	$158.96M	7.36	19.23%	―	―	―
TRDA	52 Neutral	$404.36M	-4.32	-27.11%	―	-71.42%	-248.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMT	48 Neutral	$197.48M	-3.50	-39.78%	―	―	-38.23%
CCCC	44 Neutral	$225.81M	-1.33	-59.98%	―	-10.57%	1.98%

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics highlights RNA pipeline progress and outlook

On January 8, 2026, Entrada Therapeutics reported significant 2025–early 2026 progress across its RNA-based pipeline for neuromuscular and ocular diseases, including completion of Cohort 1 dosing in the global Phase 1/2 MAD ELEVATE-44-201 study of ENTR-601-44 in Duchenne muscular dystrophy (DMD), transition to the open-label Phase 2 portion, and receipt of Rare Pediatric Disease Designation from the U.S. FDA in December 2025. The company has initiated dosing in the Phase 1/2 MAD ELEVATE-45-201 trial of ENTR-601-45, secured U.K. authorization to start a Phase 1/2 MAD study of ENTR-601-50 in DMD patients amenable to exon 50 skipping, plans regulatory filings for ENTR-601-51 in 2026, and continues to support Vertex’s ongoing global Phase 1/2 trial of VX-670 in myotonic dystrophy type 1, targeting completion of the MAD portion’s enrollment and dosing in the first half of 2026. Entrada also expanded into ophthalmology by selecting ENTR-801 in December 2025 as its first ocular clinical candidate for Usher syndrome type 2A, supported by robust preclinical data, and indicated that around 15,000 US and European patients may be addressable by exon 13 skipping; coupled with a reported cash runway into the third quarter of 2027 and a high-profile investor presentation scheduled for January 14, 2026 at the J.P. Morgan Healthcare Conference, these developments underscore the company’s intent to solidify its position as a leading player in RNA-based therapies for high-unmet-need genetic diseases.

The most recent analyst rating on (TRDA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.